Lukas Biomedical

Lukas Biomedical EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lukas Biomedical (6814.TWO) as of Oct 27, 2026 is -81.15 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -92.14 M TWD — a change of -11.93% (higher).

EBITDA

-81.15 MTWD

YoY

-11.93%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lukas Biomedical is 2025 -81.15 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lukas Biomedical was 2024 -92.14 M TWD. It decreases by -11.93% higher compared to the previous year.

The Lukas Biomedical EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-5.05 M TWD
Jan 1, 2019
-7.03 M TWD
Jan 1, 2020
-6.48 M TWD
Jan 1, 2021
-43.06 M TWD
Jan 1, 2022
-48.47 M TWD
Jan 1, 2023
-43.56 M TWD
Jan 1, 2024
-92.14 M TWD
Jan 1, 2025
-81.15 M TWD
The Lukas Biomedical EBITDA history
YEAREBITDAYoY
-81.15 MTWD-11.93%
-92.14 MTWD+111.52%
-43.56 MTWD-10.12%
-48.47 MTWD+12.55%
-43.06 MTWD+564.45%
-6.48 MTWD-7.81%
-7.03 MTWD+39.13%
-5.05 MTWD+103.59%
-2.48 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lukas Biomedical Stock analysis

What does Lukas Biomedical do? Lukas Biomedical, Inc. generates revenue through the lease and sale of medical equipment, as well as the research, design, development, and manufacture of immune cell products. The company offers beauty cosmetics, skin care products, and daily necessities such as dental floss, chewing gum, chewing spray, and dry hair products. Its makeup series includes eye shadow gel, eye color palette, lip gloss, lipstick, and lip wax. The firm provides services like brand authorization, management consulting, property leasing, and medical equipment leasing under an experience charging model for care institutions and medical management. The company’s products target consumers in the beauty and healthcare sectors, with medical equipment leased to care institutions and medical management entities. Immune cell products are developed for medical applications, while beauty and daily necessity products cater to personal care markets. The firm’s service model combines brand authorization with property and equipment leasing to support operational experience in healthcare facilities. Lukas Biomedical’s revenue streams include direct sales of medical equipment, lease agreements for medical devices, and the sale of immune cell products, beauty cosmetics, and daily necessities. Care institutions and medical management companies are key clients for leasing services, while beauty product lines serve individual consumers and retail channels. The experience charging model integrates brand authorization and management consulting to enhance service offerings for healthcare providers. Lukas Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lukas Biomedical stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lukas Biomedical is -81.15 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lukas Biomedical changed from -92.14 M TWD to -81.15 M TWD, representing a -11.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Lukas Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Lukas Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lukas Biomedical

All Key Metrics — Lukas Biomedical